Kimberly Perez, MD
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kimberly Perez, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:21 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05546411 · A Trial of NIS793 With FOLFIRINOX in Pancreatic CancerKimberly Perez, MD · terminated · Pancreatic Cancer, Resectable Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma · principal investigator
- Ph2NCT04386057 · LY3214996 +/- HCQ in Pancreatic CancerKimberly Perez, MD · completed · Pancreatic Cancer, Advanced Cancer · principal investigator
- Ph2NCT04197310 · Cabozantinib and Nivolumab for Carcinoid TumorsDana-Farber Cancer Institute · completed · Carcinoid Tumor, Carcinoid Tumor of GI System, Neuroendocrine Tumors · principal investigator
- Ph1NCT03520790 · Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic CancerDana-Farber Cancer Institute · terminated · Pancreatic Cancer · principal investigator
- Ph1NCT03316599 · Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic CancerDana-Farber Cancer Institute · completed · Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:22 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in pancreatic cancer.